ACZONE

LOE Approaching

dapsone

NDATOPICALGEL
Approved
Jul 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of dapsone gel in treating acne vulgaris is not known. 12.3 Pharmacokinetics An open-label study compared the pharmacokinetics of dapsone after dapsone gel, 5%, (110 ± 60 mg/day) was applied twice daily (~BSA 22.5%) for 14 days (n=18) with a single…

Pharmacologic Class:

Sulfone

Clinical Trials (4)

NCT01931150Phase 3Completed

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Started Aug 2013
11 enrolled
Cetuximab-induced Papulopustular (Acneiform) Rash Who HaveMetastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
NCT00344006Phase 3Completed

Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria

Started Jun 2006
1,395 enrolled
Malaria, Falciparum
NCT00371735Phase 3Completed

Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria

Started Apr 2006
900 enrolled
Malaria, Falciparum
NCT00000802Phase 3Completed

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides